Definium Therapeutics, Inc. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Definium Therapeutics, Inc. stock issued during period, value, new issues for the quarter ending 2026-06-30 was $758.73M.
- Definium Therapeutics, Inc. stock issued during period, value, new issues for the quarter ending 2024-12-31 was $0.00, a 100.00% decline year-over-year.
- Definium Therapeutics, Inc. stock issued during period, value, new issues for the quarter ending 2024-09-30 was $69.97M, a 2167.30% increase year-over-year.
- Definium Therapeutics, Inc. stock issued during period, value, new issues for the quarter ending 2024-06-30 was $0.00, a 100.00% decline year-over-year.
- Definium Therapeutics, Inc. stock issued during period, value, new issues for fiscal 2025 was $242.82M, a 3.65% increase from fiscal 2024.
- Definium Therapeutics, Inc. stock issued during period, value, new issues for fiscal 2024 was $234.27M, a 2894.59% increase from fiscal 2023.
- Definium Therapeutics, Inc. stock issued during period, value, new issues for fiscal 2023 was $7.82M, a 81.50% decline from fiscal 2022.
- Definium Therapeutics, Inc. stock issued during period, value, new issues for fiscal 2022 was $42.30M, a 48.37% decline from fiscal 2021.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2026-06-30 | $758.73M 10-Q · filed 2026-08-06 | |
| 2025-12-31 | $242.82M 10-K · filed 2026-02-26 | |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $234.27M 10-K · filed 2026-02-26 |
| 2024-09-30 | $69.97M 10-Q · filed 2025-11-06 | $237.15M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $170.26M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-03-31 | $164.30M 10-Q · filed 2025-11-06 | $171.54M derived: sum of 4 quarters · filed 2025-11-06 |
| 2023-12-31 | $2.88M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $7.82M 10-K · filed 2025-03-06 |
| 2023-09-30 | $3.09M 10-Q · filed 2024-11-07 | $5.89M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $1.27M 10-Q · filed 2024-08-13 | $44.15M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $583.00K 10-Q · filed 2024-05-08 | |
| 2022-12-31 | $947.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $42.30M 10-K · filed 2024-02-28 |
| 2022-09-30 | $41.35M 10-Q · filed 2023-11-02 | |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $81.92M 10-K · filed 2023-03-09 |
| 2021-09-30 | -$4.00K 10-Q · filed 2022-11-10 | |
| 2021-06-30 | -$186.00K 10-Q · filed 2022-08-11 | |
| 2021-03-31 | $82.11M 10-Q · filed 2022-05-16 | |
| 2020-12-31 | $71.19M 10-K · filed 2022-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cronos Group Inc. (CRON) | $1.223B | ||
| Tilray Brands, Inc. (TLRY) | United States | $0.554B | -5.97 |
| Canopy Growth Corp (CGC) | $0.395B | ||
| USANA HEALTH SCIENCES INC (USNA) | United States | $0.264B | -17.90 |
| Niagen Bioscience, Inc. (NAGE) | United States | $0.238B | 15.72 |
| FITLIFE BRANDS, INC. (FTLF) | United States | $0.087B | 16.59 |
| MANNATECH INC (MTEX) | United States | $0.014B | |
| NATURAL ALTERNATIVES INTERNATIONAL INC (NAII) | United States | $0.011B | -1.16 |
| Synergy CHC Corp. (SNYR) | United States | $0.001B | |
| Functional Brands Inc. (MEHA) | United States | $0.001B |